KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. Wakelee, H. A., Liberman, M., Kato, T., Tsuboi, M., Lee, S., He, J., Gao, S., Chen, K., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G., Bylicki, O., Rodriguez-Abreu, D., Chaft, J. E., Novello, S., Yang, J., Keller, S. M., Samkari, A., Spicer, J. LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001043181100006